CA-ARKX-LABORATORIES
17.11.2020 07:02:08 CET | Business Wire | Press release
ArkX Laboratories , a leading provider of advanced far-field voice-capture technology, has appointed Redtree Solutions, the largest Pan-European electronic representative in the semiconductor industry, as the exclusive sales representative for its production-ready EveryWord™ voice solution in the Europe, Middle East and Africa (EMEA) marketplace.
This announcement coincides with growing demand from Fortune 1000 companies, OEMs, and start-ups in the region who want to bring their voice-enabled smart products and devices to market. The EveryWord™ portfolio offers a production-ready path that delivers an unmatched voice experience while mitigating risk, reducing development costs, and accelerating their time-to-market.
Featuring Cirrus Logic's SoundClear™ and FlexArray™ technologies, ArkX's advanced line of production-ready voice capture solutions outperform other existing solutions in far-field voice capture and deliver a far-superior voice experience to consumers. The products are Alexa-compatible and meet or exceed all requirements for the Amazon Voice Services (AVS) qualifications. In addition to Alexa, EveryWord™ is compatible with other platforms such as Google, Siri, Cortana, AliGenie, Baidu/Kitt.ai, Tencent, and Sensory. EveryWord™ voice solutions can be customized for a company's eco-system and applied to a wide range of products, including speakers, soundbars, televisions, appliances, voice controllers, and gadgets. For smart home applications, the modules can be installed in hubs, ceilings, and in-wall.
"The ArkX EveryWord portfolio solves the toughest problems facing innovative OEMs today, including capturing voice at a greater distance, around corners, in the presence of blaring TV, and other noisy and reverberative environments without having to lower playback volume," said ArkX CEO Eric Bauswell. "EveryWord truly outperforms the performance of standard far-field voice solutions by so large a margin that consumers will never want to go back to the 'old' technology."
Covering 19 countries with more than 500 active customers, Redtree will help accelerate ArkX Labs' market penetration in the region by generating greater awareness of the company's solutions and providing on-the-ground support to ArkX Labs' expanding customer base.
"We were impressed with the innovation and superior far-field performance of the EveryWord™ solutions. It's a huge leap forward and certainly the best far-field solutions ever seen on the marketplace over our 10+ years' experience in this segment," said Steve Judge, Redtree Solutions Managing Director. "The addition of ArkX's EveryWord™ voice solutions represent a strategic addition to our electronic component portfolio that will have appeal to many of our customers operating in the smart home, broadband telecom, consumer, robotic, automotive, and industrial marketplaces."
ArkX Executive Vice President Michael Lang added, "Redtree's experience, expertise, and support structure provides the perfect fit to help us expand our reach beyond existing North American and Asian markets."
The product line offers clear performance advantages for capturing voice commands from three times the standard distance, around corners, noisy and reflective environments, and without lowering playback volume. Additionally, EveryWord™ technology provides a unique ability to identify and to suppress speech from TV or other single-point noise sources.
EveryWord™ technology does not require source-ducking for reliable interaction, provides linear, circular, square, triangular, or 3D mic array geometries, and requires fewer microphones. The technology features ultra-low power battery operation for wake-on-word, and the flexibility for placement of microphones allows for in-wall, ceiling, or dashboard solutions. The 3D mic array versus other linear beam-forming approaches enables fewer blind spots and increased performance while incorporating fewer redundant microphone arrays for coverage.
About ArkX Laboratories
ArkX Laboratories, a joint venture between product development pioneer, Surfaceink, and consumer electronics manufacturer Ark Electronics USA brings an exceptional voice experience to the marketplace. Our next generation of advanced, high-performance far-field voice capture solutions, featuring Cirrus Logic and NXP technology, are Amazon pre-qualified and production-ready. ArkX provides Fortune 1000, OEMs, and start-ups who want their own branded, voice-enabled IoT products and smart devices with the ability to reduce their development time and costs and accelerate their time-to-market while mitigating the risk. For more information, please visit www.arkxlabs.com .
About Redtree Solutions
Redtree Solutions is the largest Pan-European Representative company in the region. More than 40 people provide service, speak local languages, and cover 19 countries with more than 500 active customers. Redtree invests in next-generation technologies for the benefit of its customers and is dedicated to their success. The Redtree application team is devoted to helping customers find the most optimized architecture for your Electronic systems, with the help of their partners' solutions and expertise. Redtree is headquartered near Oxford, UK. For more information, please visit www.redtree-solutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom